Limits...
Pleurotus ostreatus opposes mitochondrial dysfunction and oxidative stress in acetaminophen-induced hepato-renal injury.

Naguib YM, Azmy RM, Samaka RM, Salem MF - BMC Complement Altern Med (2014)

Bottom Line: Supplementation with Pleurotus ostreatus significantly reduced APAP-induced elevated levels of ALT, AST, GDH, creatinine, BUN, KIM-1and MDA, while GSH level, and GSH-Px and SOD activities were significantly increased.Our findings were further validated by histopathology; treatment with Pleurotus ostreatus significantly decreased APAP-induced cell necrosis in liver and kidney tissues.We report here that the antioxidant effect of Pleurotus ostreatus opposes mitochondrial dysfunction and oxidative stress accompanying APAP over-dose, with subsequent clinically beneficial effects on liver and kidney tissues.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Physiology, Faculty of Medicine, Menoufia University, Menoufia, Egypt. yahya.naguib@med.menofia.edu.eg.

ABSTRACT

Background: Acetaminophen (APAP)-induced toxicity is a predominant cause of acute hepatic and renal failure. In both humans and rodents toxicity begins with a reactive metabolite that binds to proteins. This leads to mitochondrial dysfunction and nuclear DNA fragmentation resulting in necrotic cell death. Pleurotus ostreatus (an edible oyster mushroom) is well recognized as a flavourful food, as well as a medicinal supplement. In the present study, we evaluated the role of Pleurotus ostreatus in the protection against APAP-induced hepato-renal toxicity. We also explored the mechanism by which Pleurotus ostreatus exerts its effects.

Methods: Ninety adult male Swiss albino mice were divided into three groups (30 mice/group). Mice were offered normal diet (control and APAP groups), or diet supplemented with 10% Pleurotus ostreatus (APAP + Pleurotus ostreatus) for 10 days. Mice were either treated with vehicle (control group, single intra-peritoneal injection.), or APAP (APAP and APAP + Pleurotus ostreatus groups, single intra-peritoneal injection, 500 mg/kg), 24 hours after the last meal.

Results: APAP increased serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) glutamate dehydrogenase (GDH), creatinine, blood urea nitrogen (BUN), urinary kidney injury molecule-1 (KIM-1), and hepatic and renal malondialdehyde (MDA) content. APAP decreased hepatic and renal glutathione (GSH) content, as well as glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) activities. Supplementation with Pleurotus ostreatus significantly reduced APAP-induced elevated levels of ALT, AST, GDH, creatinine, BUN, KIM-1and MDA, while GSH level, and GSH-Px and SOD activities were significantly increased. Our findings were further validated by histopathology; treatment with Pleurotus ostreatus significantly decreased APAP-induced cell necrosis in liver and kidney tissues.

Conclusions: We report here that the antioxidant effect of Pleurotus ostreatus opposes mitochondrial dysfunction and oxidative stress accompanying APAP over-dose, with subsequent clinically beneficial effects on liver and kidney tissues.

Show MeSH

Related in: MedlinePlus

Anti-oxidant properties of Pleurotus ostreatus. (A) Liver and kidney GSH levels in control (white column), APAP treated (black column) and APAP + 10% Pleurotus ostreatus treated (grey column) groups. (B) Liver and kidney MDA levels in control (white column), APAP treated (black column) and APAP + 10% Pleurotus ostreatus treated (grey column) groups. (C) Liver and kidney GSH-Px levels in control (white column), APAP treated (black column) and APAP + 10% Pleurotus ostreatus treated (grey column) groups. (D) Liver and kidney SOD levels in control (white column), APAP treated (black column) and APAP + 10% Pleurotus ostreatus treated (grey column) groups. (Significant = p < 0.05, *significant when compared to the control group, • significant when compared to the APAP treated group. Number of mice = 10/group).
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4301462&req=5

Fig3: Anti-oxidant properties of Pleurotus ostreatus. (A) Liver and kidney GSH levels in control (white column), APAP treated (black column) and APAP + 10% Pleurotus ostreatus treated (grey column) groups. (B) Liver and kidney MDA levels in control (white column), APAP treated (black column) and APAP + 10% Pleurotus ostreatus treated (grey column) groups. (C) Liver and kidney GSH-Px levels in control (white column), APAP treated (black column) and APAP + 10% Pleurotus ostreatus treated (grey column) groups. (D) Liver and kidney SOD levels in control (white column), APAP treated (black column) and APAP + 10% Pleurotus ostreatus treated (grey column) groups. (Significant = p < 0.05, *significant when compared to the control group, • significant when compared to the APAP treated group. Number of mice = 10/group).

Mentions: Hepatic GSH was significantly lower in the APAP group when compared to the control group (2.9 ± 0.32 vs 10.1 ± 1.6 μM/mg protein, P < 0.05). Hepatic GSH in APAP + Pleurotus ostreatus group was significantly higher than in the APAP group (9.16 ± 0.49 μM/mg protein, P < 0.05). There was no statistically significant difference in hepatic GSH between APAP + Pleurotus ostreatus and control groups (P > 0.05). Renal GSH was significantly lower in the APAP group compared to the control group (3.3 ± 0.64 vs 6.1 ± 1.2 μM/mg protein, P < 0.05). Renal GSH in APAP + Pleurotus ostreatus group was significantly higher than in the APAP group (5.9 ± 1.1 μM/mg protein, P < 0.05). There was no statistically significant difference in renal GSH between APAP + Pleurotus ostreatus and control groups (P > 0.05) (Figure 3A).


Pleurotus ostreatus opposes mitochondrial dysfunction and oxidative stress in acetaminophen-induced hepato-renal injury.

Naguib YM, Azmy RM, Samaka RM, Salem MF - BMC Complement Altern Med (2014)

Anti-oxidant properties of Pleurotus ostreatus. (A) Liver and kidney GSH levels in control (white column), APAP treated (black column) and APAP + 10% Pleurotus ostreatus treated (grey column) groups. (B) Liver and kidney MDA levels in control (white column), APAP treated (black column) and APAP + 10% Pleurotus ostreatus treated (grey column) groups. (C) Liver and kidney GSH-Px levels in control (white column), APAP treated (black column) and APAP + 10% Pleurotus ostreatus treated (grey column) groups. (D) Liver and kidney SOD levels in control (white column), APAP treated (black column) and APAP + 10% Pleurotus ostreatus treated (grey column) groups. (Significant = p < 0.05, *significant when compared to the control group, • significant when compared to the APAP treated group. Number of mice = 10/group).
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4301462&req=5

Fig3: Anti-oxidant properties of Pleurotus ostreatus. (A) Liver and kidney GSH levels in control (white column), APAP treated (black column) and APAP + 10% Pleurotus ostreatus treated (grey column) groups. (B) Liver and kidney MDA levels in control (white column), APAP treated (black column) and APAP + 10% Pleurotus ostreatus treated (grey column) groups. (C) Liver and kidney GSH-Px levels in control (white column), APAP treated (black column) and APAP + 10% Pleurotus ostreatus treated (grey column) groups. (D) Liver and kidney SOD levels in control (white column), APAP treated (black column) and APAP + 10% Pleurotus ostreatus treated (grey column) groups. (Significant = p < 0.05, *significant when compared to the control group, • significant when compared to the APAP treated group. Number of mice = 10/group).
Mentions: Hepatic GSH was significantly lower in the APAP group when compared to the control group (2.9 ± 0.32 vs 10.1 ± 1.6 μM/mg protein, P < 0.05). Hepatic GSH in APAP + Pleurotus ostreatus group was significantly higher than in the APAP group (9.16 ± 0.49 μM/mg protein, P < 0.05). There was no statistically significant difference in hepatic GSH between APAP + Pleurotus ostreatus and control groups (P > 0.05). Renal GSH was significantly lower in the APAP group compared to the control group (3.3 ± 0.64 vs 6.1 ± 1.2 μM/mg protein, P < 0.05). Renal GSH in APAP + Pleurotus ostreatus group was significantly higher than in the APAP group (5.9 ± 1.1 μM/mg protein, P < 0.05). There was no statistically significant difference in renal GSH between APAP + Pleurotus ostreatus and control groups (P > 0.05) (Figure 3A).

Bottom Line: Supplementation with Pleurotus ostreatus significantly reduced APAP-induced elevated levels of ALT, AST, GDH, creatinine, BUN, KIM-1and MDA, while GSH level, and GSH-Px and SOD activities were significantly increased.Our findings were further validated by histopathology; treatment with Pleurotus ostreatus significantly decreased APAP-induced cell necrosis in liver and kidney tissues.We report here that the antioxidant effect of Pleurotus ostreatus opposes mitochondrial dysfunction and oxidative stress accompanying APAP over-dose, with subsequent clinically beneficial effects on liver and kidney tissues.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Physiology, Faculty of Medicine, Menoufia University, Menoufia, Egypt. yahya.naguib@med.menofia.edu.eg.

ABSTRACT

Background: Acetaminophen (APAP)-induced toxicity is a predominant cause of acute hepatic and renal failure. In both humans and rodents toxicity begins with a reactive metabolite that binds to proteins. This leads to mitochondrial dysfunction and nuclear DNA fragmentation resulting in necrotic cell death. Pleurotus ostreatus (an edible oyster mushroom) is well recognized as a flavourful food, as well as a medicinal supplement. In the present study, we evaluated the role of Pleurotus ostreatus in the protection against APAP-induced hepato-renal toxicity. We also explored the mechanism by which Pleurotus ostreatus exerts its effects.

Methods: Ninety adult male Swiss albino mice were divided into three groups (30 mice/group). Mice were offered normal diet (control and APAP groups), or diet supplemented with 10% Pleurotus ostreatus (APAP + Pleurotus ostreatus) for 10 days. Mice were either treated with vehicle (control group, single intra-peritoneal injection.), or APAP (APAP and APAP + Pleurotus ostreatus groups, single intra-peritoneal injection, 500 mg/kg), 24 hours after the last meal.

Results: APAP increased serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) glutamate dehydrogenase (GDH), creatinine, blood urea nitrogen (BUN), urinary kidney injury molecule-1 (KIM-1), and hepatic and renal malondialdehyde (MDA) content. APAP decreased hepatic and renal glutathione (GSH) content, as well as glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) activities. Supplementation with Pleurotus ostreatus significantly reduced APAP-induced elevated levels of ALT, AST, GDH, creatinine, BUN, KIM-1and MDA, while GSH level, and GSH-Px and SOD activities were significantly increased. Our findings were further validated by histopathology; treatment with Pleurotus ostreatus significantly decreased APAP-induced cell necrosis in liver and kidney tissues.

Conclusions: We report here that the antioxidant effect of Pleurotus ostreatus opposes mitochondrial dysfunction and oxidative stress accompanying APAP over-dose, with subsequent clinically beneficial effects on liver and kidney tissues.

Show MeSH
Related in: MedlinePlus